Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (4017)	6/6/2001 8:53:12 AM
From: Michael Young	Respond to of 52153

KOSP broke out to a multi-year high yesterday on big volume - for it. This stock in some ways highlights the relative strength of biotech over traditional tech at the moment. KOSP has no earnings, and scrips for Niaspan, while at record levels, are lower than most investors had hoped. Yet the market is willing to bid up the stock in anticipation that Advicor will be huge. And it will be huge if given the proper marketing muscle. Contrast that to most techs. The market is unwilling to give the benefit of the doubt to those stocks. Except maybe the large semi-equips. MIKE